TOKYO, Jan 11 (Bernama-BUSINESS WIRE) -- Toshiba Corporation’s (TOKYO:6502) Storage & Electronic Devices
Solutions Company today expanded its line-up of low-voltage N-channel power
MOSFETs with the addition of 100V N-channel power MOSFETs supporting 4.5V logic
level drive for quick chargers. The two new MOSFETs of the “U-MOS VIII-H
Series”, “TPH4R10ANL” and “TPH6R30ANL,” start shipments from today.
Wednesday, January 11, 2017
TOSHIBA'S NEW LOW-CAPACITANCE TVS DIODES FOR HIGH-SPEED INTERFACES IN MOBILE DEVICES DELIVER THE INDUSTRY'S LEADING-CLASS PROTECTION PERFORMANCE
TOKYO, Jan 11 (Bernama-BUSINESS WIRE)
-- Toshiba Corporation’s (TOKYO:6502) Storage & Electronic Devices
Solutions Company today announced the launch of a new line-up of
low-capacitance TVS diodes [1] for use in high-speed
interfaces in mobile devices, including smartphones, tablet PCs and wearable
devices. The new diodes deliver the industry’s leading-class[2] protection
performance. The line-up covers ten products to protect high-speed interfaces,
including USB 3.0/3.1 and HDMI, from electronic discharge (ESD) and noise.
Shipments start from today.
KEIO PLAZA HOTEL TOKYO STARTS AN ORIGINAL TOKYO SIGHTSEEING LIMOUSINE TOUR WITH ENGLISH-SPEAKING CHAUFFEURS TO EXPLORE JAPANESE SAKE BREWERIES
TOKYO, Jan 10 (Bernama-BUSINESS WIRE) -- Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, started a special sightseeing limousine tour of sake breweries and a museum with optional English-speaking chauffeurs in collaboration with Keio Jidousha Co., Ltd (Keio Taxi Company) in December, 2016. This plan is offered in commemoration of the opening of the Keio Plaza Hotel Tokyo’s highest category of accommodation facility “Premier Grand Club Floors,” and in response to the strong demand from overseas guests interested in experiencing Japanese culture at a more personal level in the comfort of a luxury vehicle.
This chauffeured tour will take guests to two of three Japanese sake breweries located in western Tokyo, including Ishikawa Brewery, Tamura Brewery, and Ozawa Brewery. Also, guests will be taken to “Kushi Kanzashi (Traditional ornate hair combs) Museum.” This tour can take up to six guests in chauffeur driven minivans, with an option to hire English speaking chauffeurs.
MURATA MACHINERY'S AUTONOMOUS FLOOR SCRUBBER "BUDDY" OFFICIALLY DEPLOYED AT SINGAPORE CHANGI AIRPORT
SINGAPORE and KYOTO, Japan, Jan 11
(Bernama-AsiaNet) -- MURATA MACHINERY SINGAPORE PTE. LTD. is pleased to
announce on January 11 the official procurement and deployment of our
autonomous floor scrubber and drier, "Buddy," at Singapore Changi
Airport by Changi Airport Group (S) Pte. Ltd. With our independently developed
"Intelligent Transfer Navigation System" ("It's Navi (R)"),
Buddy enhances cleaning efficiency and reduces the manpower required for
cleaning large spaces, especially during night-time cleaning operations.
TCL RANKS AMONG IDG'S 2016-2017 GLOBAL TOP 50 CE BRANDS AT CES 2017
TCL Quantum Dot TV Receives Global Display Tech
Innovation Award of the Year
TCL C15BA Named Global Best Integrated Large Screen Product of the Year
LAS VEGAS, Jan 11 (Bernama-BUSINESS WIRE) -- TCL (The Creative Life), the world’s third largest TV manufacturer, today announced that the company was honored by International Data Group (IDG) as 2016-2017 Global Top 50 CE Brands and 2016-2017 Top 10 CE Brands from China, and won the Global Display Tech Innovation Award of the Year for TCL Quantum Dot TV. Besides, a TCL product named C15BA received the award of Global Best Integrated Large Screen Product of the Year.
Tuesday, January 10, 2017
BIOLINE LAUNCHES THE FULL RANGE OF EPIK™ MIRNA ASSAYS
CINCINNATI, Jan 10 (Bernama-GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the
EPIK™ miRNA Select Assays, originally developed for the study of individual
microRNA (miRNA) molecules. In collaboration with MiRXES, Bioline released 800
EPIK™ miRNA Select Assays in March 2016 and this has now been increased to
include all of the organisms listed on the miRBase release 21, which represents
over 27,000 miRNA assays. Recent studies continue to show the clinical value of
individual miRNA molecules which are released from tissues and cells. The
expression of certain individual miRNA molecules correlates with specific
disease conditions making them promising biomarker candidates for the early
detection of disease, prognosis and monitoring of treatment in both humans and
other organisms.
RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference
TEL-AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced the presentation of an abstract relating to YELIVA®, the Company’s proprietary, first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor, at the 2017 Cholangiocarcinoma Foundation Annual Conference, on February 2, 2017, in Salt Lake City, UT.
The abstract, entitled ‘Targeting Sphingosine Kinase-2 for the Treatment of Cholangiocarcinoma (CCA)’1, was authored by scientists from the Mayo Clinic, Apogee Biotechnology Corp. (Apogee), the Medical University of South Carolina (MUSC) and RedHill. It will be presented by one of its authors, Dr. Lewis R. Roberts, M.B., Ch.B., Ph.D, a gastroenterologist and hepatologist at Mayo Clinic and the External Co-Chair of The Cancer Genome Atlas (TCGA) Cholangiocarcinoma Project of the National Cancer Institute (NCI).
SOURCE: RedHill Biopharma Ltd.
Subscribe to:
Posts (Atom)